Evolocumab has significantly reduced the risk of cardiovascular events in FOURIER Outcomes Study
The FOURIER trial to evaluate whether Evolocumab ( Repatha ) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease ( ASCVD ) met its prim ...
read article